Specialty: Cardiovascular disease, Primary sub-specialty: Heart failure
Conditions
Interventions
Following informed consent all participants will have a medical and medication history taken. They will undergo ECG, blood pressure, breathlessness and heart rate measurements.
All pa
Sponsors
University Hospitals Bristol NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age over 18 years 2. Able to provide informed consent 3. Diagnosis of heart failure made more than one month prior to enrollment 4. On medication for heart failure including ACEi/ARB and B-blocker 5. Has 4 week supply of ACE/ARB and B blocker 6. Live in postcode areas BS1 – BS16 7. Able to read and understand instructions in English
Exclusion criteria
Exclusion criteria: 1. Medication given by partner or other care-provider 2. Use of dosette box 3. History of advanced dementia 4. Planned travel away for home for more than 7 consecutive days during the study period 5. 3G and WiFi signal absent or very poor in patient’s home 6. Expected to change dose of ACEi/ARB or BB during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of ACE/ARB and Beta Blocker heart failure tablets taken during the study period, calculated from the pill count taken by the research nurse at baseline, 4, and 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mean difference between groups, in the proportion of patients with chronic heart failure taking >80% of prescribed pills (ACEi/ARB and BB) over a four-week period 2. Mean difference between groups in change in MMAS-8 scores measured at baseline, 4, and 8 weeks between baseline and the end of the treatment block 3. Mean difference between groups in change in urine metabolite numbers, measured at baseline, 2, 4, 6 and 8 weeks between baseline and the end of the treatment block | — |
Countries
United Kingdom
Contacts
Public ContactRuth Bowles
Outcome results
None listed